FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2991570475> ?p ?o ?g. }

• W2991570475 abstract "Abstract Background Most ovarian cancer patients are diagnosed at a late stage with 85% of them relapsing after surgery and standard chemotherapy; for this reason, new treatments are urgently needed. Ovarian cancer has become a candidate for immunotherapy by reason of their expression of shared tumor-associated antigens (TAAs) and private mutated neoantigens (NeoAgs) and the recognition of the tumor by the immune system. Additionally, the presence of intraepithelial tumor infiltrating lymphocytes (TILs) is associated with improved progression-free and overall survival of patients with ovarian cancer. The aim of active immunotherapy, including vaccination, is to generate a new anti-tumor response and amplify an existing immune response. Recently developed NeoAgs-based cancer vaccines have the advantage of being more tumor specific, reducing the potential for immunological tolerance, and inducing robust immunogenicity. Methods We propose a randomized phase I/II study in patients with advanced ovarian cancer to compare the immunogenicity and to assess safety and feasibility of two personalized DC vaccines. After standard of care surgery and chemotherapy, patients will receive either a novel vaccine consisting of autologous DCs pulsed with up to ten peptides (PEP-DC), selected using an agnostic, yet personalized, epitope discovery algorithm, or a sequential combination of a DC vaccine loaded with autologous oxidized tumor lysate (OC-DC) prior to an equivalent PEP-DC vaccine. All vaccines will be administered in combination with low-dose cyclophosphamide. This study is the first attempt to compare the two approaches and to use NeoAgs-based vaccines in ovarian cancer in the adjuvant setting. Discussion The proposed treatment takes advantage of the beneficial effects of pre-treatment with OC-DC prior to PEP-DC vaccination, prompting immune response induction against a wide range of patient-specific antigens, and amplification of pre-existing NeoAgs-specific T cell clones. Trial registration This trial is already approved by Swissmedic (Ref.: 2019TpP1004) and will be registered at http://www.clinicaltrials.gov before enrollment opens." @default.
• W2991570475 created "2019-12-05" @default.
• W2991570475 creator A5004309131 @default.
• W2991570475 creator A5005580505 @default.
• W2991570475 creator A5006319046 @default.
• W2991570475 creator A5007749781 @default.
• W2991570475 creator A5017724230 @default.
• W2991570475 creator A5027245893 @default.
• W2991570475 creator A5035745685 @default.
• W2991570475 creator A5042043616 @default.
• W2991570475 creator A5045600693 @default.
• W2991570475 creator A5049523087 @default.
• W2991570475 creator A5052684432 @default.
• W2991570475 creator A5055480892 @default.
• W2991570475 creator A5066247182 @default.
• W2991570475 creator A5081248161 @default.
• W2991570475 creator A5087479651 @default.
• W2991570475 date "2019-11-26" @default.
• W2991570475 modified "2023-10-10" @default.
• W2991570475 title "A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma" @default.
• W2991570475 cites W1116139823 @default.
• W2991570475 cites W1501252326 @default.
• W2991570475 cites W1782844421 @default.
• W2991570475 cites W1961928411 @default.
• W2991570475 cites W1973091654 @default.
• W2991570475 cites W1976002760 @default.
• W2991570475 cites W1979568379 @default.
• W2991570475 cites W1980296501 @default.
• W2991570475 cites W1989167514 @default.
• W2991570475 cites W1992699637 @default.
• W2991570475 cites W1995970041 @default.
• W2991570475 cites W2007026865 @default.
• W2991570475 cites W2009720434 @default.
• W2991570475 cites W2010427283 @default.
• W2991570475 cites W2011122139 @default.
• W2991570475 cites W2015707371 @default.
• W2991570475 cites W2018929154 @default.
• W2991570475 cites W2030610701 @default.
• W2991570475 cites W2037228209 @default.
• W2991570475 cites W2040594411 @default.
• W2991570475 cites W2047382244 @default.
• W2991570475 cites W2060906121 @default.
• W2991570475 cites W2065545617 @default.
• W2991570475 cites W2067301515 @default.
• W2991570475 cites W2068514555 @default.
• W2991570475 cites W2080062352 @default.
• W2991570475 cites W2086473033 @default.
• W2991570475 cites W2097192869 @default.
• W2991570475 cites W2098677932 @default.
• W2991570475 cites W2105651363 @default.
• W2991570475 cites W2121919466 @default.
• W2991570475 cites W2136313650 @default.
• W2991570475 cites W2137049683 @default.
• W2991570475 cites W2137074525 @default.
• W2991570475 cites W2140419616 @default.
• W2991570475 cites W2150627675 @default.
• W2991570475 cites W2150678612 @default.
• W2991570475 cites W2150950736 @default.
• W2991570475 cites W2160195286 @default.
• W2991570475 cites W2172036797 @default.
• W2991570475 cites W2340267638 @default.
• W2991570475 cites W2340558243 @default.
• W2991570475 cites W2345394027 @default.
• W2991570475 cites W2403289604 @default.
• W2991570475 cites W2414799134 @default.
• W2991570475 cites W2518214177 @default.
• W2991570475 cites W2555228033 @default.
• W2991570475 cites W2724264513 @default.
• W2991570475 cites W2728365508 @default.
• W2991570475 cites W2774113098 @default.
• W2991570475 cites W2793742921 @default.
• W2991570475 cites W2797967795 @default.
• W2991570475 cites W2890246395 @default.
• W2991570475 cites W2896379242 @default.
• W2991570475 cites W2911692766 @default.
• W2991570475 cites W2950859100 @default.
• W2991570475 cites W2952417505 @default.
• W2991570475 cites W2952607757 @default.
• W2991570475 cites W2963698421 @default.
• W2991570475 cites W2979293383 @default.
• W2991570475 doi "https://doi.org/10.1186/s12967-019-02133-w" @default.
• W2991570475 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6880492" @default.
• W2991570475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31771601" @default.
• W2991570475 hasPublicationYear "2019" @default.
• W2991570475 type Work @default.
• W2991570475 sameAs 2991570475 @default.
• W2991570475 citedByCount "41" @default.
• W2991570475 countsByYear W29915704752020 @default.
• W2991570475 countsByYear W29915704752021 @default.
• W2991570475 countsByYear W29915704752022 @default.
• W2991570475 countsByYear W29915704752023 @default.
• W2991570475 crossrefType "journal-article" @default.
• W2991570475 hasAuthorship W2991570475A5004309131 @default.
• W2991570475 hasAuthorship W2991570475A5005580505 @default.
• W2991570475 hasAuthorship W2991570475A5006319046 @default.
• W2991570475 hasAuthorship W2991570475A5007749781 @default.
• W2991570475 hasAuthorship W2991570475A5017724230 @default.
• W2991570475 hasAuthorship W2991570475A5027245893 @default.
• W2991570475 hasAuthorship W2991570475A5035745685 @default.
• W2991570475 hasAuthorship W2991570475A5042043616 @default.

• next